Biomarkers for Huntington's Disease Improving Clinical Outcomes
Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Cham
Springer International Publishing
2023, 2023
|
| Edition: | 1st ed. 2023 |
| Series: | Contemporary Clinical Neuroscience
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers
- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics
- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers
- MRI - non-invasive functional MRI measures
- The evolution of clinical trial methodology.-Digital biomarkers
- The future of telehealth
- Summary and future trends